EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The Cardiorenal Protective Effects of Low-Dose Tolvaptan in Peritoneal Dialysis Patients with Volume Overload

Xinyang Li, Panpan Chao, Chongyu Zhang, Wenpeng Cui

American Journal of Nephrology · 2026-10-08 · 1-1

DOI: 10.1159/ajn/ablag013 ↗
AbstractBibliografische Angaben

Abstract

Introduction: The aims of the study were to compare the efficacy and safety of low-dose tolvaptan versus conventional therapy in peritoneal dialysis (PD) patients with volume overload and to evaluate its effects on cardiac and renal functions. Methods: The control group received conventional therapy, while the tolvaptan group received oral tolvaptan (15 mg) every other day for 6 months. Clinical and safety data were collected at baseline, 3, 6, and 9 months (3 months post-discontinuation). Primary outcomes included changes in volume status, residual renal function, and cardiac function. Results: Sixty patients with PD who underwent regular follow-up at the Second Hospital of Jilin University between May 1, 2023, and December 31, 2025, were randomized 1:1 to tolvaptan or control (n = 30 each); 56 completed follow-up (28 per group). Overhydration decreased in both groups, with a greater reduction in the tolvaptan group (linear trend test, p = 0.033). A 24-h urine volume in the tolvaptan group increased during the first week (p = 0.02) and remained higher throughout the treatment period (all p < 0.05), although total water removal (urine volume plus peritoneal ultrafiltration volume) did not differ between the 2 groups at any follow-up time point (all p > 0.05). A 24-h peritoneal ultrafiltration in the tolvaptan group showed an initial decrease, followed by an increase. Residual renal glomerular filtration rate (GFR) in the tolvaptan group remained stable at 3 and 6 months (p = 0.695, p = 0.178), but decreased after discontinuation (p < 0.001), whereas in the control group, residual renal GFR was lower than baseline at all time points (p < 0.05). Ln (BNP) levels declined in both groups (p = 0.392). The left ventricular ejection fraction in the tolvaptan group increased during the first 6 months (p = 0.019) but decreased at 9 months, with no change in controls. Ln (LVMI) decreased in the tolvaptan group but increased in the control group, with a significant difference in trends (p < 0.001). One patient had hypernatremia, which resolved, no other adverse events. During the follow-up period, no episodes of PD-related peritonitis, PD technique failure, or all-cause mortality were observed in either group. Conclusion: With strict sodium monitoring, low-dose tolvaptan safely improved volume status and delayed residual renal function decline. It also showed potential cardioprotective effects, primarily reflected by a reduction in LVMI. However, the long-term effects on hard clinical outcomes, including mortality and technique survival, require further investigation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →